Capstone Therapeutics Corp. (NASDAQ:CAPS) Sees Significant Decline in Short Interest

Capstone Therapeutics Corp. (NASDAQ:CAPS) was the recipient of a significant decrease in short interest in March. As of March 31st, there was short interest totaling 134,793 shares, a decrease of 14.3% from the March 15th total of 157,346 shares. Based on an average trading volume of 132,777 shares, the days-to-cover ratio is presently 1.0 days. Approximately 3.6% of the shares of the stock are short sold.

Capstone Therapeutics Price Performance

Shares of Capstone Therapeutics stock opened at $0.40 on Friday. The stock has a market capitalization of $3.67 million, a price-to-earnings ratio of -0.11 and a beta of -1.27. The firm’s 50-day moving average price is $0.61 and its two-hundred day moving average price is $0.79. The company has a current ratio of 0.95, a quick ratio of 0.35 and a debt-to-equity ratio of 0.29. Capstone Therapeutics has a 1-year low of $0.38 and a 1-year high of $3.29.

Institutional Investors Weigh In On Capstone Therapeutics

A hedge fund recently bought a new stake in Capstone Therapeutics stock. DRW Securities LLC acquired a new stake in Capstone Therapeutics Corp. (NASDAQ:CAPS) in the 4th quarter, according to the company in its most recent filing with the SEC. The fund acquired 125,422 shares of the company’s stock, valued at approximately $91,000. DRW Securities LLC owned about 1.51% of Capstone Therapeutics as of its most recent filing with the SEC. 2.55% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Capstone Therapeutics in a report on Monday, December 29th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock has a consensus rating of “Sell”.

Capstone Therapeutics Company Profile

Capstone Therapeutics Corp., a biotechnology company, develops novel peptides and other molecules for helping patients with under-served medical conditions in the United States. It develops Apo E mimetic peptide molecule AEM-28 and its analogs that have completed Phase Ia and Phase Ib/IIa clinical trials for lipoprotein metabolism. The company was formerly known as OrthoLogic Corp. and changed its name to Capstone Therapeutics Corp. in May 2010. Capstone Therapeutics Corp. was founded in 1987 and is headquartered in Tempe, Arizona.